Stay updated with breaking news from Crpc Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reported new Phase 1b/2 data from lead KRAS-mutated metastatic colorectal cancer (mCRC) clinical program showing objective response rate and median...
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights News provided by Share this article SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. "Over the last severa...